Elusys Therapeutics
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Century Dr Ste 260, Parsippany, New Je...Phone Number
(973) 808-0222Website
www.elusys.comRevenue
$13 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Elusys Therapeutics
Elusys Therapeutics specializes in innovative medical countermeasures aimed at providing effective protection against infectious agents and public health threats. The company focuses on the development and commercialization of biodefense solutions, particularly for government partners, and has successfully advanced its product ANTHIM, a monoclonal anthrax antitoxin, to commercial availability. Elusys has secured significant funding from various government agencies to enhance U.S. biosecurity against potential anthrax attacks. Their primary clients include strategic government entities such as the Department of Defense and public health agencies.Explore more
Elusys Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elusys Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Elusys Therapeutics is spiking on competitors!
Elusys Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Elusys Therapeutics recently announced quarterly report
Check if Elusys Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Elusys Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Elusys Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Elusys Therapeutics
Product Launch: Get notified when Elusys Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Elusys Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Elusys Therapeutics
Compare insights from companies similar to Elusys Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Elusys Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Elusys Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Elusys Therapeutics.
Elusys Therapeutics financials insights
Gather financial insights about Elusys Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Elusys Therapeutics Tech Stack
A closer look at the technologies used by Elusys Therapeutics
Elusys Therapeutics News & Media
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United KingdomObiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax
PARSIPPANY, N.J., Dec. 2, 2020 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. Obiltoxaximab is indicated in all...Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthrax
European Commission Decision Anticipated in November 2020 PARSIPPANY, N.J., Oct. 8, 2020 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elusys Therapeutics
Sign Up For FreeTo access detailed company insights
Elusys Therapeutics specializes in innovative medical countermeasures aimed at providing effective protection against infectious agents and public health threats. The company focuses on the development and commercialization of biodefense solutions, particularly for government partners, and has successfully advanced its product ANTHIM, a monoclonal... Read More
